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Abstract
Background Pleomorphic invasive lobular cancer (pleomor-
phic ILC) is a rare variant of ILC that is characterized by a
classic ILC-like growth pattern combined with an infiltrative
ductal cancer (IDC)-like high nuclear atypicality. There is an
ongoing discussion whether pleomorphic ILC is a
dedifferentiated form of ILC or in origin an IDC with a sec-
ondary loss of cohesion. Since gene promoter hypermethyla-
tion is an early event in breast carcinogenesis and thus may
provide information on tumor progression, we set out to com-
pare the methylation patterns of pleomorphic ILC, classic ILC
and IDC. In addition, we aimed at analyzing the methylation
status of pleomorphic ILC.
Methods We performed promoter methylation profiling of 24
established and putative tumor suppressor genes by
methylation-specific multiplex ligation-dependent probe am-
plification (MS-MLPA) analysis in 20 classical ILC, 16 pleo-
morphic ILC and 20 IDC cases.
Results We found that pleomorphic ILC showed relatively
low TP73 and MLH1 methylation levels and relatively high
RASSF1A methylation levels compared to classic ILC.
Compared to IDC, pleomorphic ILC showed relatively low
MLH1 and BRCA1 methylation levels. Hierarchical cluster
analysis revealed a similar methylation pattern for pleomor-
phic ILC and IDC, while the methylation pattern of classic
ILC was different.
Conclusion This is the first report to identify TP73,
RASSF1A, MLH1 and BRCA1 as possible biomarkers to dis-
tinguish pleomorphic ILC from classic ILC and IDC.
Keywords Sporadic breast cancer . Lobular breast cancer .
Pleomorphic lobular breast cancer . DNA hypermethylation .
MS-MLPA . Epigenetics
1 Introduction
Invasive lobular breast cancer (ILC) is the second most prev-
alent histological breast cancer type that accounts for 10–15%
of all breast cancers [1, 2]. ILC differs from invasive ductal
carcinoma (IDC) in biology, histology, clinical presentation
and response to therapy (reviewed in [3]). In contrast to ductal
tumors, most lobular tumors show loss of E-cadherin expres-
sion, which often results from inactivating gene mutation and
subsequent loss of heterozygosity or promoter hypermethyla-
tion [4]. Indeed, conditional knock-out mouse models have
shown that somatic inactivation of E-cadherin leads to ILC
development and progression [5, 6]. Among the eight differ-
ent ILC variants described, classic ILC and pleomorphic ILC
are the most common ones [3, 7]. Although the exact frequen-
cy of these ILC subtypes has not extensively been document-
ed, approximately 60% of all ILC cases is classic and approx-
imately 13 % is pleomorphic (reviewed in [3]) .
Phenotypically, classic ILC is composed of small regular
low grade and dissociated cells with intra-cytoplasmic
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vacuoles and small nuclei that exhibit a highly trabecular in-
filtrative growth pattern, often distributed in targetoid patterns
around uninvolved ducts [8]. Pleomorphic ILC shows a sim-
ilar growth and invasion pattern, but is composed of high
grade polygonal cells with eccentric and highly pleomorphic
nuclei. Furthermore, pleomorphic ILC tumors have been re-
ported to be significantly larger than classic ILC tumors, and
pleomorphic ILC patients often present with lymph node in-
volvement and a higher rate of metastatic disease compared to
classical ILC [9]. Moreover, the overall survival and recur-
rence rates of pleomorphic ILC patients are worse compared
to classic ILC patients [10], indicating that pleomorphic ILC is
a more aggressive form of breast cancer than classic ILC.
At the molecular level, classic and pleomorphic ILCs show
similarities and differences. Both variants lack expression of
basal markers like cytokeratin (CK)5 and CK14, but expresses
the luminal epithelial markers CK8 and CK18 [11, 12]. ILCs
are usually ‘luminal’ type breast cancers that express the es-
trogen receptor (ER) gene and genes involved in ER activa-
tion, including the progesterone receptor (PR) gene [13, 14].
Cytosolic translocation of p120-catenin due to inactivation of
E-cadherin is a hallmark of ILC, whereas classic and pleomor-
phic ILCs do not over-express the epidermal growth factor
receptor (EGFR) gene [1, 15, 16]. While most classic ILCs
lack expression of HER2 (ERBB2) [1], up to 81 % of pleo-
morphic ILCs express HER2 [17]. Moreover, although the
somatic TP53 mutation frequency in pleomorphic ILC may
be as high as 46 %, this is a rare event in classic ILC (approx-
imately 6 %), suggesting a role for p53 loss in the etiology of
pleomorphic ILC [17–19]. These findings are supported by
observations in mammary-specific E-cadherin and p53
knock-out mice that develop a mouse variant of pleomorphic
ILC [6]. Furthermore, in contrast to classic ILC, pleomorphic
ILC often expresses the apocrine differentiation marker gross
cystic disease fluid protein 15 (GCDFP15) and the androgen
receptor (AR) [17, 20]. The origin of pleomorphic ILC tumors
is still under debate and, since results from conditional mouse
models have suggested that all lobular cancer types are evo-
lutionary linked (reviewed in [21]), It is currently unclear
whether pleomorphic ILC is a dedifferentiated form of classic
ILC or whether it evolves from ductal type tumors. The dif-
ferential diagnosis between these breast cancer subtypes is
important because surgery planning of ILC requires pre-
operative MRI, due to an often more diffuse and multifocal
growth pattern of lobular tumors and a higher incidence of
contralateral tumors [22].
In cancer, DNA methylation is often disturbed and can act
as a driving force during tumor progression [23, 24] (reviewed
in [25]). DNAmethylation occurs by the enzymatic transfer of
a methyl group onto the carbon-5 position of a cytosine (often
part of a cytosine phosphate guanosine (CpG) dinucleotide),
which can result in gene silencing [26]. Promoter hyperme-
thylation of tumor suppressor genes is considered to be an
early event in carcinogenesis since high methylation levels
have been found in columnar cell lesions, the earliest recog-
nized breast cancer precursors [27]. Hence, methylation pat-
terns may give insight in tumor progression and, thus, shed
light on the precursor origin of pleomorphic ILC tumors. In
light of the possible future extrapolation to methylation detec-
tion in biopsy, blood, nipple fluid and urine samples, DNA
hypermethylation is a promising area in the clinical biomarker
field. DNA hypermethylation analyses can be performed on
formalin-fixed tissues and, thus, are suited for molecular pro-
filing and the identification of markers that predict therapeutic
responsiveness.
Here we have identified promoter methylation patterns
in pleomorphic ILC in relation to ILC and IDC to identify
pleomorphic ILC biomarkers. Methylation was assessed by
methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA), a highly reproducible tech-
nique that only requires small amounts (10 ng) of short
DNA fragments and that shows high concordance with oth-
er established techniques such as quantitative multiplex
methylation-specific PCR [28, 29]. MS-MLPA can be used
in samples with mixed populations of cells. As long as 30 %
of methylated DNA/tumor DNA is present in the sample,
the methylation status will be recognized correctly [30]. We
assessed the promoter methylation status of 24 tumor sup-
pressor genes and compared 16 pleomorphic ILC, 20 clas-
sic ILC and 20 IDC cases. We found that the methylation
patterns of classic ILC and IDC were comparable, and that
the classic ILC and IDC profiles were mildly different from
pleomorphic ILC. Furthermore, we found that the methyl-
ation status of the RASSF1A, TP73, MLH1 and BRCA1
gene promoters can be used as stratification markers to dis-
tinguish pleomorphic ILC from classic ILC and IDC.
2 Materials and methods
2.1 Patient material
Patient samples were derived from the archives of the
Departments of Pathology at the University Medical Centre
Utrecht, the Radboud University Medical Centre, Nijmegen,
The Netherlands, the Institute of Pathology, Paderborn,
Germany, and the Department of Pathology, Bács-Kiskun
County Teaching Hospital, Kecskemét, Hungary. The clinico-
pathological characteristics of the patient samples are provid-
ed in Table 1. Classic and pleomorphic ILC and IDC cases
were selected based on examination of haematoxylin and eo-
sin (H&E)-stained slides by at least two pathologists. The use
of left-over material was approved by the Tissue Science
Committee of the UMC Utrecht [31]. Histological grades
were assessed according to the Nottingham modification of
the Scarff-Bloom-Richardson grading system [32]. ER and
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PR were considered positive when ≥10 % of the cells showed
positive nuclear staining. HER2 was scored according to the
modified DAKO scoring system, where only a score of 3+
was considered positive. The mitotic activity index (MAI)
was assessed as reported before [33].
2.2 Methylation-specific multiplex ligation-dependent
probe amplification
H&E stained sections were used to reveal pre-invasive le-
sions, necrosis and admixed lymphocytic infiltrates and to
guide micro-dissections for DNA extraction. Areas with ne-
crosis, dense lymphocytic infiltrates and pre-invasive lesions
were intentionally avoided. All areas selected for micro-
dissection had a tumor percentage of at least 70 %. Tumor
tissue was derived from 4 μm thick sections (5 to 10,
formalin-fixed paraffin embedded) and DNAwas isolated by
overnight incubation in lysis buffer (50mMTris–HCl, pH 8.0;
0.5 % Tween 20) with proteinase K (10 mg/ml, Roche) at
56 °C, followed by boiling for 10 min. After a 5 min centri-
fugation step (12,000 g), 5 μl supernatant was used for MLPA
analysis according to the manufacturer’s instructions, using
theME001-C2 methylation kit (MRC-Holland). The principle
of MS-MLPA has been described elsewhere [28] and the PCR
and data analysis procedures were performed as reported be-
fore [27]. The ME001-C2 MS-MLPA probe mix contains 26
probes, detecting the methylation status of promoter CpG sites
of 24 established and putative tumor suppressor genes
(Table 2) that are frequently silenced by hypermethylation in
tumors, but not in blood-derived DNA of healthy individuals.
In addition, we included 15 reference probes. The cumulative
methylation index (CMI) was calculated as the sum of the
methylation percentage of all genes, as described before [34].
2.3 Statistics
Statistic calculations and ROC curve analyses were performed
using IBM SPSS statistics v20.0 (SPSS Inc., Chicago, IL,
USA). Two-sided p<0.05 was considered significant.
Absolute methylation levels were used to calculate p-values
upon comparing classic ILC, pleomorphic ILC and IDC sam-
ples, using the Student’s t-test or Mann–Whitney U Test, and
the Kruskal-Wallis test. Through Bonferroni-Holm correction
of all p-values we excluded false-positives caused by multiple
comparisons. Logistic regression analysis was used to reveal
the best (combination of) genes able to discriminate pleomor-
phic ILC from classic ILC and/or IDC. A backward stepwise
method was used until the most predictive variables remained.
Unsupervised hierarchical clustering (Euclidean metric) using
the statistical program R was performed on Z-scores to iden-
tify relevant clusters.
3 Results and discussion
Kruskal-Wallis one-way ANOVA analysis was carried out to
assess differential methylation patterns in our non-parametric
methylation data of the three breast cancer subtypes, i.e.,
Table 1 Clinicopathological
characteristics of breast cancer
patients
Classic ILC Pleomorphic ILC IDC
Feature Grouping N (%) N (%)
N 20 16 20
Range 52–88 43–80 44–87
Histological grade 1 8 (40.0) 0 (0.0) 5 (25.0)
2 6 (30.0) 5 (31.3) 5 (25.0)
3 5 (25.0) 11 (68.8) 10 (50.0)
Not available 1 (5.0) 0 (0.0) –
MAI (%) Mean 3 20 16.5
Range 0–26 9–100 0–8
Not available 1 (5.0) 1 (6.3) –
Lymph node status Negativea 11 (55.0) 8 (50.0) 7 (35.0)
Positiveb 7 (35.0) 8 (50.0) 13 (65.0)
Not available 2 (10.0) – –
Receptor status ER positive 19 (95.0) 14 (87.5) 15 (75.0)
PR positive 10 (50.0) 10 (62.5) 13 (65.0)
Her2 positive 0 (0.0) 0 (0.0) 3 (15.0)
Tumor size (cm) ≤2.0 1 (5.0) 4 (25.0) 8 (40.0)
>2.0 18 (90.0) 12 (75.0) 12 (60.0)
Not available 1 (5.0) – –
a : negative = N0 or N0(i+); b : positive = ≥N1mi (according to TNM 7th edition, 2010)
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classic ILC, pleomorphic ILC and IDC (Fig. 1; patient
samples listed in Table 1). Sixteen of the 24 genes tested
(listed in Table 2), including BRCA1, showed significant dif-
ferences between the groups. However, after correction for
multiple comparisons only the methylation patterns of TP73
(p<0.002), MLH1_b (p<0.002) and RASSF1A_x (p<0.002)
were found to be significantly different between the three
breast cancer subtypes (Fig. 2).
A (post hoc) Mann–Whitney test followed by multiple
comparisons correction was carried out, using the 16 genes
derived from the above Kruskal-Wallis analysis, to specify the
differences between classic and pleomorphic ILCs. By doing
so, we found that the methylation patterns of TP73, MLH1_y
and RASSF1A_xwere significantly different between the clas-
sic and pleomorphic ILCs. When compared to classic ILCs,
pleomorphic ILCs showed less promoter methylation of the
MLH1_y (p=0.003) and TP73 (p=0.001) genes (Fig. 2), while
the promoter methylation of the RASSF1A gene was found to
be higher in pleomorphic ILCs (p=0.001). The CMI of the
pleomorphic ILCs was not significantly different from that of
classic ILCs (353.3 versus 390.0, respectively; p=0.437). In
logistic regression analyses TP73 (p=0.017) and RASSF1A
(p=0.005) showed a joint independent discriminative value
for pleomorphic ILCs versus classic ILCs (area under the
curve (AUC) 0.888, CI 0.764-1.000, p<0.001), with a com-
bined receiver operating characteristic (ROC) curve-based
sensitivity and specificity of 81 and 100 %, respectively.
After correction for multiple comparisons, we found that
the methylation levels of both MLH1_y (p=0.001) and
BRCA1 (p=0.002) were significantly lower in pleomorphic
ILCs than in IDCs (Fig. 2). The mean CMI of pleomorphic
ILCs was not significantly different from that of IDCs (353.3
vs. 392.6, respectively; p=0.357), indicating that the overall
methylation patterns of these two breast cancer subgroups
were similar. Logistic regression analysis showed that only
BRCA1 methylation (p=0.002) had an independent
Table 2 Probes directed against the CpG islands of 24 tumor suppressor genes in the MS-MLPA kit (ME001-C2, MRC-Holland)
Length Gene Chromosome Mapview Full name
142 TIMP3 22q12.3 22-031.527795 TIMP metallopeptidase inhibitor 3
148 APC 5q22.2 05-112.101357 Adenomatosis Polyposis Coli
161 CDKN2A 9p21.3 09-021.985276 Cyclin-Dependent Kinase Inhibitor 2A
167 MLH1_aa 3p22.2 03-037.009621 MutL Homolog 1
184 ATM 11q22.3 11-107.599044 Ataxia Telangiectasia Mutated
193 RARB 3p24.2 03-025.444559 Retinoic Acid Receptor, beta
211 CDKN2B 9p21.3 09-021.998808 Cyclin-Dependent Kinase Inhibitor 2B
220 HIC1 17p13.3 17-001.905107 Hypermethylated In Cancer 1
238 CHFR 12q24.33 12-131.974372 Checkpoint with Forkhead and Ring finger domains
246 BRCA1 17q21.31 17-038.530811 Breast Cancer 1
265 CASP8 2q33.1 02-201.830871 Caspase 8
274 CDKN1B 12p13.1 12-012.761863 Cyclin-Dependent Kinase Inhibitor 1B
292 PTEN 10q23.3 10-089.612348 Phosphatase and Tensin homolog
301 BRCA2 13q12.3 13-031.787722 Breast Cancer 2
319 CD44 11p13 11-035.117389 CD44 molecule
328 RASSF1A_aa 3p21.31 03-050.353298 Ras Association (RalGDS/AF-6) domain Family member 1
346 DAPK1 9q21.33 09-089.303075 Death-Associated Protein Kinase 1
353 VHL 3p25.3 03-010.158426 Von Hippel-Lindau tumor suppressor
373 ESR1 6q25.1 06-152.170883 Estrogen Receptor 1
382 RASSF1A_b* 3p21.31 03-050.353347 Ras Association (RalGDS/AF-6) domain Family member 1
400 TP73 1p36.32 01-003.558977 Tumor Protein p73
409 FHIT 3p14.2 03-061.211918 Fragile Histidine Triad
427 CADM1 11q23.3 11-114.880585 Cell Adhesion Molecule 1
436 CDH13 16q23.3 16-081.218219 Cadherin 13
454 GSTP1 11q13.2 11-067.107774 Glutathione S-transferase pi 1
463 MLH1_ba 3p22.2 03-037.010000 MutL Homolog 1
a For these genes two probe sets against different CpG sites (a and b) are present
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discriminative value for pleomorphic ILC versus IDC (area
under the curve (AUC) 781, CI 0.623-0.939, p=0.004), with
a ROC curve-based sensitivity and specificity of 75 and 81%,
respectively.
In order to determine if the absolute MS-MLPA values of
our samples clearly defined our three breast cancer subtypes,
we performed hierarchical Euclidean cluster analysis on all
genes tested (Fig. 3a) and on the four genes that showed sig-
nificant differences in the Mann–Whitney tests (Fig. 3b). Both
cluster analyses revealed some clustering of pleomorphic ILC
samples with IDC samples, while classic ILC samples usually
formed separate clusters with other IDC samples.
The different advantages and possibilities of DNA methyl-
ation analyses for disease stratification and prognostication
A
B
C
Fig. 1 Representative H&E
images of classic and
pleomorphic ILC and IDC.
Classic ILC is characterized by
small regular cells, small nuclei
and a low mitotic rate (a). The
formation of single (‘indian’) files
is a common characteristic of
classic ILC (enlarged in right
image). Pleomorphic ILCs
display polygonal cells and
frequent mitoses (b). The nuclei
are often eccentric, highly
pleomorphic and show distinctive
nucleoli (enlarged in right image,
arrows). IDC tumors are not
characterized by specific features
like ILC (c). In contrast to ILC,
IDC often shows formation of
ducts within the tumor (left and
right image). All size bars indicate
25 μm
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Fig. 2 Methylation differences between classic and pleomorphic ILC.
Scatter dot plots of the absolute methylation values that were found to
be significantly different between the three breast cancer types. TP73,
MLH1_y and RASSF1A_x were significantly different between
pleomorphic and classic ILC, while only MLH1_y and BRCA1 were
significantly different between pleomorphic ILC and IDC. All p-values
are derived from the Mann–Whitney analysis. The horizontal bars
represent the median
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have led to a large amount of reports in the literature, also on
breast cancer. However, the vast majority of these reports has
so far focused on IDC, and we are unaware of any report on
DNA methylation in pleomorphic ILC. Interestingly, in two
reports the DNA methylation patterns were compared in ILC
and IDC, and it was found that they were very similar in these
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Fig. 3 Cluster analysis of the breast cancer methylation data. (a)
Hierarchical cluster analysis of Z-scores based on absolute methylation
values by MS-MLPA of all interrogated genes in classic ILC (light grey),
pleomorphic ILC (red) and IDC (black). (b) Hierarchical cluster analysis
of Z-scores based on absolute methylation values of the four significantly
differentially methylated genes according to the Mann–Whitney analysis
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two breast cancer subtypes [35, 36]. Our results are in agree-
ment with this notion, while pleomorphic ILC appeared to
exhibit a distinct methylation pattern with a CMI similar to
that of classic ILC and IDC.
BRCA1, MLH1 and RASSF1A are established tumor sup-
pressor genes and TP73 is a putative tumor suppressor gene.
BRCA1 andMLH1 are involved in DNA repair and their func-
tional loss causes an accumulation of gene defects.
Interestingly, we found a significant association between the
presence of MLH1_x (p=0.013) and BRCA1 (p=0.013) pro-
moter methylation and a high MAI (>12), and between
MLH1_x and BRCA1 promoter methylation (p=0.004) (data
not shown). Previously, BRCA1 promoter methylation has
been observed in 10–15 % of all sporadic breast cancer pa-
tients [37, 38]. Only 4–5% of the lobular breast tumors carry a
deleterious BRCA1 mutation [39], and none of the 11 previ-
ously analyzed ILC samples showed BRCA1 hypermethyla-
tion [37]. As we found that the MLH1 and BRCA1 methyla-
tion levels were lower in pleomorphic ILC compared to IDC,
they may not be suitable as therapeutic targets, but they may
be used as biomarkers.
To test the reproducibility of MS-MLPA, we have previ-
ously taken along 10 primary breast tumor samples in dupli-
cate in at least 8 separate MS-MLPA runs (unpublished data).
By doing so, we found that the TP73, MLH1_y, RASSF1A_x
and BRCA1 probes have an average standard deviation of
0.01, 0.01, 0.05 and 0.02 per sample, respectively. Based on
these findings, we anticipate that the between-group differ-
ences observed for TP73 and RASSF1A_x are reproducible
and reliable. The differences between groups observed for
MLH1_y and BRCA1 are, however, less pronounced and
may be the result of technical variability. We, therefore, rec-
ommend validating these findings by an independent highly
sensitive and quantitative technique.
TP73 is subject to alternative splicing, and the use of an
alternative promoter results in different p73 isoforms that ex-
hibit contrasting effects on tumor development [40]. Although
TP73 promoter methylation has been correlated with a poor
survival of breast cancer patients [41], this methylation also
impairs binding of the transcriptional repressor ZEB1, which
may result in an increase in TP73 expression [42].
Unfortunately, studies reporting TP73 methylation levels in
normal breast tissue are scarce and not combined with protein
or RNA expression analyses [27, 43], and TP73 methylation
studies in ILC have not been reported yet. As we found TP73
promoter methylation to be relatively low in pleomorphic ILC
compared to classic ILC, it may serve as a biomarker, whereas
it is considered less suited as a target for therapy. Further
studies are needed to determine the effect of TP73methylation
on protein expression and to determine the functional conse-
quences in pleomorphic ILC.
RASSF1A promoter methylation was found to be higher in
pleomorphic ILC than in classic ILC. Although uncommon,
RASSF1A polymorphisms and deletions have been encoun-
tered and RASSF1A promoter hypermethylation has been
found to frequently occur in different tumor types [44].
About 70–85 % of ILC and IDC cases show RASSF1A hyper-
methylation [35, 45]. Also, hypermethylation of RASSF1A in
pre-operative serum of breast cancer patients has been found
to serve as an independent prognostic marker correlated with a
poor overall survival [46]. Since RASSF1A hypermethylation
is rarely observed in normal breast tissues, it is considered to
be an early event in breast cancer development [46, 47] and, as
such, it may serve as a promising breast cancer biomarker.
RASSF1 is a member of the RASSF family of genes (RASSF
1–8), and gives rise to 8 different isoforms due to alternative
splicing and alternative promoter usage [48]. Next to the
RASSF proteins, RAF and phosphatidylinositol 3-kinase
(PI3K) are also known as RAS effectors, i.e., proteins that
specifically bind the GTP-bound form of RAS. In contrast to
RAF and PI3K, which control proliferation and survival, the
RASSF genes are known to act as tumor suppressors [48].
RASSF1A null-mice show an increased incidence of sponta-
neous tumor formation, a decreased survival rate and an in-
creased susceptibility for mutagens (reviewed in [48]). In ad-
dition, it has been found that exogenous expressions of
RASSF1A in different tumor cell lines reduces their viability,
proliferation and invasion [48]. These findings, combined
with our data showing increased RASSF1A promoter methyl-
ation in pleomorphic ILC, renders RASSF1A into an interest-
ing and functional biomarker for lobular breast cancer.
In conclusion, our data indicate that the promoter methyl-
ation signature of the TP73, MLH1, RASSF1A and BRCA1
genes may serve as a biomarker to distinguish pleomorphic
ILC from classic ILC and IDC. Since pleomorphic ILC is
considered to be an aggressive breast cancer variant, and since
pre-operative MRI is favorable for ILC patients but not for
IDC patients, pleomorphic ILC biomarkers may be useful for
treatment design in cases where a pathological distinction be-
tween ILC and IDC is questionable. Future research is needed
to confirm our findings in an independent patient group and to
evaluate the potential of the respective methylation markers as
therapeutic targets.
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